Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Melatonin for Insomnia
NCT06802913Phase 1Recruiting
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of melatonin in insomnia disorder (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Sleep Onset Latency at Day 1. Started Jul 2025; status: recruiting.
02
Drugs
melatonin
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT06802913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802913.